Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate‐to‐severe plaque psoriasis

This study evaluated the pharmacokinetics (PK), efficacy, safety, and tolerability of bleselumab – a fully‐human anti‐CD40 monoclonal recombinant IgG4. Patients with moderate‐to‐severe psoriasis were randomized on day 1 to receive bleselumab or placebo on days 1, 15 and 29 in a dose‐escalation of bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Anil Kumar, Mysore S., Papp, Kim, Tainaka, Ryo, Valluri, Udaya, Wang, Xuegong, Zhu, Tong, Schwabe, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032846/
https://www.ncbi.nlm.nih.gov/pubmed/29679478
http://dx.doi.org/10.1002/bdd.2130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032846/
https://www.ncbi.nlm.nih.gov/pubmed/29679478
http://dx.doi.org/10.1002/bdd.2130

Ejemplares similares